Dr. Ya-Chi Chen holds a Doctor of Pharmacy degree from the University of Iowa and brings over 20 years of experience in drug development, specializing in clinical pharmacology and translational medicine. Her expertise covers small molecules, biologics, and antibody-drug conjugates across virology, immunology, and oncology.
A passionate advocate of science-driven, model-informed drug development (MIDD), Dr. Chen leverages translational insights and cross-functional collaboration to accelerate development and improve patient outcomes. She has held senior leadership positions at leading biopharmaceutical companies, including Executive Director at Revolution Medicines, Senior Director at Gilead Sciences, and Director at Roche.
Well-regarded for her contributions to precision medicine, she leads the design and implementation of clinical pharmacology strategies for NDA, BLA, and MAA submissions, with a focus on delivering the right treatment at optimal dose for each patient.